Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 148, Issue 1, Pages 8-17Publisher
WILEY
DOI: 10.1002/ijc.33197
Keywords
cancer; MYC; p53; RAS; treatment; undruggable genes
Categories
Funding
- Cancer Clinical Research Trust
Ask authors/readers for more resources
RAS, p53, and MYC are commonly altered genes in cancer, traditionally considered undruggable due to the lack of accessible hydrophobic pockets for targeting. However, recent studies have shown that low molecular weight compounds targeting these genes have anticancer activity in preclinical models, suggesting that the traditional perception of these genes being undruggable is changing.
RAS, TP53 (p53) and MYC are among the most frequently altered driver genes in cancer. Thus, RAS is the most frequently mutated oncogene, MYC the most frequently amplified gene and TP53 the most frequently mutated tumor suppressor gene and overall the most frequently mutated gene in cancer. Theoretically, therefore, these genes are highly attractive targets for cancer treatment. However, as the protein products of each of these genes lack an accessible hydrophobic pocket into which low molecular weight compounds might bind with high affinity, they have proved difficult to target and have traditionally been referred to as undruggable. Despite this branding, several low molecular weight compounds targeting each of these proteins have recently been reported to have anticancer activity in preclinical models. Indeed, several drugs inhibiting mutant KRAS, MYC overexpression or reactivating mutant p53 have undergone or are currently undergoing clinical trials. For targeting mutant KRAS and reactivating mutant p53, trials have progressed to a Phase III stage, that is, the mutant-p53 reactivating drug, APR-246 is currently being investigated in patients with myelodysplastic syndrome (MDS) and the RAS inhibitor, rigosertib is also undergoing evaluation in patients with MDS. Although there appears to be no directly acting MYC inhibitor currently being tested in a clinical trial, an anti-MYC compound, known as OmoMYC has been extensively validated in multiple preclinical models and is being developed for clinical evaluation. Based on current evidence, the traditional perception of RAS, p53 and MYC as being undruggable would appear to be coming to an end.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available